We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Presurgery Stress Tests and Beta Blockers No Longer Considered Necessary

By HospiMedica International staff writers
Posted on 16 Dec 2009
Routine perioperative stress testing provides no incremental diagnostic yield in patients at low risk for cardiac events, and indiscriminate perioperative therapy with beta-blockers can increase mortality in otherwise stable patients, claims a new report.

An article by physicians at the University of Michigan (U-M; Ann Arbor, USA) that critically evaluates costly preoperative practices was published following new guidelines released by the American College of Cardiology (ACC; Washington, DC, USA) and the American Heart Association (AHA; Dallas, TX, USA), which recommend that preoperative medications should be reserved for only high risk patients undergoing complicated surgeries.

The U-M physicians, however, went a step further by critically evaluating other costly preoperative practices, such stress testing and coronary revascularization therapies such as stenting and bypass surgery for patients with stable heart disease. More...
The authors claim that perioperative tests and treatments improve outcomes only when targeted at specific patient subsets. For example, routine perioperative stress testing provides no incremental diagnostic yield in patients at low risk for cardiac events; in fact, the authors claim, stress tests do not reliably predict potentially fatal issues such as coronary artery clots and spasms. Indiscriminate perioperative therapy with beta-blockers, they add, can increase mortality in otherwise stable patients, if dosages are not carefully monitored over months. Thus, many accepted perioperative practices conflict with the evidence and can be safely discontinued while preserving outcomes and reducing costs. The report was published ahead of print on November 30, 2009, in the Annals of Internal Medicine.

"Traditionally we've thought of stress tests as the best way to figure out whether a patient is ready for surgery," said study coauthor Vineet Chopra, M.D., a clinical assistant professor of internal medicine at the U-M medical school. "It appears that many noninvasive stress tests are not only unnecessary, but potentially misleading. Occasionally such testing may lead to unnecessary invasive testing which has its own set of risks, or unnecessary medical treatment which also has some risks attached.”

Related Links:
University of Michigan
American College of Cardiology
American Heart Association



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.